Akebia Therapeutics Inc (STU:AX9)
€ 1.04 0.028 (2.77%) Market Cap: 212.40 Mil Enterprise Value: 213.22 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Akebia Therapeutics Inc Corporate Call Transcript

Mar 30, 2022 / 10:00PM GMT
Release Date Price: €0.715 (-68.08%)
Operator

Good day, and thank you for standing by. Welcome to Akebia Therapeutics Corporate Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to turn the conference over to your first speaker today to Mercedes Carrasco, Director of Corporate Communications. Please go ahead.

Mercedes Carrasco
Akebia Therapeutics, Inc. - Director of Corporate Communications

Thank you, and thank you for attending the Akebia conference call to discuss a recent regulatory update related to vadadustat. Please note that a press release was issued on Wednesday, March 30, detailing the regulatory update, and that release is available on the Investors section of our website. For your convenience, a replay of today's call will be available on our website shortly after we conclude.

Joining me today for today's call is John Butler, Chief Executive Officer; Dave Spellman, Chief Financial Officer; Dell Faulkingham, Chief Commercial Officer; and Dr. Steven Burke, our Head of R&D and Chief Medical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot